ReviewHeliyon2024
A current era in pulsatile drug delivery system: Drug journey based on chronobiology.
Review in Heliyon, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- A multi-compartment pulsatile drug delivery system for sequential release: in vitro and in vivo evaluation.Drug delivery and translational research · 2026Article
- Circadian rhythms and chronotherapy in Alzheimer's disease: Mechanisms and therapeutic implications.Neuroprotection (Chichester, England) · 2026Review
- Delivery Strategies and Clinical Significance of Oral Colon-targeted Drug Delivery Systems.AAPS PharmSciTech · 2026Review
- Janus acoustically responsive scaffolds for sequential drug release with phase-programmed steady and pulsatile kinetics.Journal of colloid and interface science · 2025Article
- Harnessing postbiotics for liver health: Emerging perspectives.World journal of gastrointestinal pharmacology and therapeutics · 2025Review
- Nanomaterial-enabled drug delivery systems for circadian medicine: bridging direct rhythm modulation and chronotherapy.RSC advances · 2025Review
- Review
- Revealing Three-Dimensional Printing Technology Advances for Oral Drug Delivery: Application to Central-Nervous-System-Related Diseases.Pharmaceutics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Almost all biological processes in the human body are regulated by circadian rhythm, which results in drastically different biochemical and physiological conditions throughout a 24 h period. Hence, suitable drug delivery systems should be efficiently monitored to attain the required therapeutic plasma concentration and therapeutic drug responses when needed as per chrono pharmacological concepts. "Chronotherapy" is the fast and transient release of a particular quantity of drug substance post a predetermined off-release period, termed as 'lag time'. Due to rhythmic variations, it is typically unnecessary to administer a medicine drug in an unhealthy condition constantly. Pulsatile drug delivery systems have received a lot of attention in pharmaceutical development because they give a quick or rate-controlled drug release after administration, followed by an anticipated lag period. Patients with various illnesses, such as asthma, hypertension, joint inflammation, and ulcers, can benefit from a pulsatile drug delivery system. Thus, a pulsatile drug delivery system may be a potential system for managing different diseases. This review mainly focuses on pulsatile drug delivery systems. It reviews and discusses the rationale, drug release mechanism, need, and system classification. In addition, it covers mainly externally regulated pulsatile drug delivery systems and recent advances in pulsatile systems like artificial intelligence and 3D printing. It also covers the ethical issues associated with pulsatile drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.